Veriheal

AUGUST 7, 2022

New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).

Consumption 109

Consumption Patients Research and Development Data 109

The Cannigma

JANUARY 13, 2023

Treating migraine pain is one of the instances where inhaled cannabis consumption, such as smoking or vaping , is important for the right effects and speed of delivery. 1 A 2008 study found serotonin and endocannabinoid levels, including anandamide, were lower in people with chronic migraines. headaches per month.

Terpenes 132

Terpenes Strains THC Treatment 132

CannaTech

SEPTEMBER 16, 2018

Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. But this gap restricts patient access to a medicine that can offer relief to a long list of conditions including chronic pain, seizures attributed to epilepsy, as well as mood disorders such as anxiety and depression.

Education 66

Education Medicine Clinical Trials Patients 66

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Data collection.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. billion in 2025, according to Grandview Research.

Law 40

Law Seed-To-Sale Hemp Recreational 40